Clarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at ENDO 2022, the Endocrine Society’s Annual Meeting
09 juin 2022 09h05 HE
|
Clarus Therapeutics Holdings, Inc.
JATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions NORTHBROOK, Ill., June 09, 2022...
Ascendis Pharma A/S Announces Participation in ENDO Online 2020
08 juin 2020 08h15 HE
|
Ascendis Pharma
COPENHAGEN, Denmark, June 08, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical...
Novelion Therapeutics’ Subsidiary Announces New Data to be Presented at the Annual Meeting of the Endocrine Society
30 mars 2017 16h15 HE
|
Novelion Therapeutics, Inc.
VANCOUVER, British Columbia and CAMBRIDGE, Mass., March 30, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new...